Bioline RX Ltd Sponsored ADR Stock

$0.61

0.23% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Bioline RX Ltd Sponsored ADR Stock price

$0.61

-2.10 77.36% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.00 0.23%

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$49.08m
Enterprise Value	$40.28m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	2.36
P/S ratio (TTM) P/S ratio	2.88
P/B ratio (TTM) P/B ratio	3.51
Revenue (TTM) Revenue	$17.05m
EBIT (operating result TTM) EBIT	$-34.82m
Free Cash Flow (TTM) Free Cash Flow	$-30.42m
Cash position	$40.06m
EPS (TTM) EPS	$-0.45
P/E forward	negative
P/S forward	2.42
EV/Sales forward	1.98
Short interest	0.34%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Bioline RX Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	17 17	- 100%
- Direct Costs	6.51 6.51	714% 714% 38%
Gross Profit	11 11	1,418% 1,418% 62%
- Selling and Administrative Expenses	33 33	79% 79% 191%
- Research and Development Expense	11 11	27% 27% 62%
EBITDA	-33 -33	3% 3% -191%
- Depreciation and Amortization	2.30 2.30	188% 188% 13%
EBIT (Operating Income) EBIT	-35 -35	2% 2% -204%
Net Profit	-30 -30	30% 30% -177%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bioline RX Ltd Sponsored ADR Stock News

Neutral

Seeking Alpha

●

23 days ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

Neutral

PRNewsWire

●

24 days ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafo...

Neutral

PRNewsWire

●

about one month ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd.

More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office	Israel
CEO	Philip Serlin
Employees	38
Founded	2003
Website	www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now